Results 81 to 90 of about 27,341 (230)

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

Stability Indicating Liquid Chromatographic Method for the Simultaneous Determination of Rosuvastatin and Ezetimibe from Pharmaceuticals and Biological Samples

Journal of the Turkish Chemical Society, Section A: Chemistry, 2020
Fixed dose combinations of ezetimibe and rosuvastatin are well known to provide significantly superior efficacy to rosuvastatin alone in lowering total cholesterol, and triglyceride levels.
Sevinç KURBANOĞLU, Ozgur ESİM, Cansel KOSE OZKAN, Ayhan SAVAŞER , Yalcin OZKAN, Bengi USLU , Sibel ÖZKAN   +6 more
doaj  

Subgroups of Adult‐Onset Diabetes: A Prospective Follow‐Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen, Annemari Käräjämäki, Aki J. Käräjämäki, Samu Kurki, Liisa Hakaste, Olof Asplund, Johan Hultman, Kaj Lahti, Mikko Lehtovirta, Emma Ahlqvist, Tiinamaija Tuomi   +10 more
wiley   +1 more source

Ezetimibe reduces intimal hyperplasia in rabbit jugular vein graft

, 2012
BackgroundThe selective cholesterol transport inhibitor ezetimibe is widely used to prevent development of atherosclerosis in patients with hypercholesterolemia.
Maekawa, Takashi, Komori, Kimihiro, Morisaki, Kouichi, Itoh, Takeo   +3 more
core   +1 more source

Ezetimibe inhibits expression of acid sphingomyelinase in liver and intestine

, 2009
Ezetimibe inhibits cholesterol absorption in the intestine. Sphingomyelin has strong interactions with cholesterol. We investigated the effects of ezetimibe on Sphingomyelinase (SMase) expression in intestine and liver. After feeding rats with ezetimibe (
Wu, Jun, Jun Wu, Duan, Rui-Dong, Yao Zhang, Rui‐Dong Duan, Liu, Fuli, Zhang, Yao, Yajun Cheng, Fuli Liu, Cheng, Yajun, Nilsson, Åke, Åke Nilsson   +11 more
core   +1 more source

Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study

Lipids in Health and Disease, 2018
Background The utility of ezetimibe in preventing cardiovascular outcomes remains controversial. To guide future assessments of the effectiveness of ezetimibe in routine care, we evaluated how this medication has been prescribed to high-risk older adults
Kristin K. Clemens, Salimah Z. Shariff, Eric McArthur, Robert A. Hegele   +3 more
doaj   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Serious drug-induced liver disease secondary to ezetimibe [PDF]

, 2019
Ezetimibe is the first member of a new family of lipid-lowering drugs that inhibits uptake of dietary and biliary cholesterol. It was approved by the FDA in 2002 for hypercholesterolemia alone or in combination with statins.
Girbau, Anna, Castellote Alonso, José, Ariza Cardenal, Javier, Rota Roca, Rosa, Xiol Quingles, Xavier   +4 more
core   +1 more source

Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia

Lipids in Health and Disease, 2009
Background Ezetimibe (Zetia®) is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. Statin, an inhibitor of cholesterol synthesis, is the first-choice drug to reduce low-density lipoprotein ...
Aoyama Naoyoshi, Machida Yoji, Yoshida Yuki, Hatakeyama Yuko, Kosugi Rie, Tojo Taiki, Yamaoka-Tojo Minako, Masuda Takashi, Izumi Tohru   +8 more
doaj   +1 more source

Application of Box–Behnken design and desirability function in the development and optimization of self-nanoemulsifying drug delivery system for enhanced dissolution of ezetimibe

Future Journal of Pharmaceutical Sciences, 2020
This study is focused on developing and optimizing a self-nanoemulsifying drug delivery system (SNEDDS) of BCS class II drug (ezetimibe) through Box–Behnken design (BBD) and desirability function for enhanced dissolution.
Pragya Yadav, V. Rastogi, A. Verma
semanticscholar   +1 more source